Allon Therapeutics Inc NPCUF

Healthcare Biotechnology

Allon Therapeutics, Inc. is a Canada-based Company, which develops treatments for neurodegenerative diseases. The Company is engaged in pre-clinical and clinical development of proprietary neuroprotective compounds which may be applied for the potential treatment of Alzheimer's Disease, Parkinson's Disease, senile dementia, glaucoma, traumatic head injury, neuronal damage due to stroke and other conditions involving neurodegeneration. The Company's drug, davunetide, is proceeding in a pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA).

GREY:NPCUF - Post by User

Allon Therapeutics Inc

Bullboard Posts

Comment by diadon1945on Dec 12, 2012 8:58pm

136 Views

Post# 20722654

RE: RE: RE: Kickinghorse

You are correct fezguy...PPHM never got FDA approval. They reported positive trial results which they had to withdraw when they discovered a third party contractor has mixed up treatment vials...apparently it would seem between low and high dose cohorts. But none the less it was the good trial results that moved the stock price.

What is interesting is that the stock price went up to $5.50 on phase II trial results!

NPC will be announcing pivotal phase III trial results! Partnering and sales will follow quickly!

Bullboard Posts

MDA Space stock blasts off on Q3 financial results